NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

MannKind Corporation (NASDAQ: MNKD)

 
MNKD Technical Analysis
3
As on 9th Jun 2023 MNKD SHARE Price closed @ 4.03 and we RECOMMEND Buy for LONG-TERM with Stoploss of 3.72 & Buy for SHORT-TERM with Stoploss of 3.81 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

MNKDSHARE Price

Open 4.10 Change Price %
High 4.11 1 Day -0.09 -2.18
Low 3.96 1 Week -0.61 -13.15
Close 4.03 1 Month 0.22 5.77
Volume 2627900 1 Year -0.36 -8.20
52 Week High 5.63 | 52 Week Low 2.62
 
NASDAQ USA Most Active Stocks
TSLA 244.40 4.06%
TTOO 0.07 -12.50%
SOFI 8.18 0.74%
FFIE 0.33 6.45%
PONO 1.72 2.38%
AMD 124.92 3.20%
IDEX 0.06 0.00%
NKLA 0.70 14.75%
AMZN 123.43 -0.66%
AAPL 180.96 0.22%
 
NASDAQ USA Top Gainers Stocks
IDRA 8.64 1909.30%
REDU 3.41 1075.86%
CTXRW 0.14 600.00%
NDRAW 0.03 200.00%
METXW 0.05 150.00%
GLSPT 33.43 138.62%
BCAC 22.71 125.30%
JCIC 22.08 116.68%
AURCW 0.04 100.00%
NOVVW 0.02 100.00%
 
NASDAQ USA Top Losers Stocks
OTIC 0.01 -91.67%
PTRAW 0.23 -89.59%
PTIXW 0.01 -66.67%
AGBAW 0.02 -66.67%
MLACW 0.02 -60.00%
MILEW 0.06 -53.85%
RCRTW 0.02 -50.00%
LOTZW 0.01 -50.00%
GSMGW 0.01 -50.00%
DKDCW 0.01 -50.00%
 
 
MNKD
Daily Charts
MNKD
Intraday Charts
Whats New @
Bazaartrend
MNKD
Free Analysis
 
MNKD Important Levels Intraday
RESISTANCE4.32
RESISTANCE4.23
RESISTANCE4.17
RESISTANCE4.11
SUPPORT3.95
SUPPORT3.89
SUPPORT3.83
SUPPORT3.74
 
MNKD Forecast April 2024
4th UP Forecast6
3rd UP Forecast5.37
2nd UP Forecast4.98
1st UP Forecast4.59
1st DOWN Forecast3.47
2nd DOWN Forecast3.08
3rd DOWN Forecast2.69
4th DOWN Forecast2.06
 
MNKD Weekly Forecast
4th UP Forecast4.94
3rd UP Forecast4.65
2nd UP Forecast4.47
1st UP Forecast4.29
1st DOWN Forecast3.77
2nd DOWN Forecast3.59
3rd DOWN Forecast3.41
4th DOWN Forecast3.12
 
MNKD Forecast2024
4th UP Forecast10.27
3rd UP Forecast8.27
2nd UP Forecast7.03
1st UP Forecast5.8
1st DOWN Forecast2.26
2nd DOWN Forecast1.03
3rd DOWN Forecast-0.21
4th DOWN Forecast-2.21
 
 
MNKD Other Details
Segment EQ
Market Capital 1187133312.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
MNKD Address
MNKD
 
MNKD Latest News
 
Your Comments and Response on MannKind Corporation
 
MNKD Business Profile
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity used for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of Treprostinil (Tyvaso DPI) used for the treatment of pulmonary arterial hypertension; and Thirona Bio to evaluate the therapeutic potential of TGF-ß inhibitor for the treatment of pulmonary fibrosis. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California. Address: 30930 Russell Ranch Road, Westlake Village, CA, United States, 91362
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service